Baricitinib in Idiopathic Granulomatous Mastitis
Study Details
Study Description
Brief Summary
This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This study is aim to explore the mechanism of baricitinib in regulating the occurrence and development of idiopathic granulomatous mastitis, as well as the clinical classification and potential markers of idiopathic granulomatous mastitis. The target population of interest in this study is patients with non-lactating mastitis, which requires core needle biopsy pathology to indicate mastitis or biopsy pathology of palpable mass indicates chronic interstitial cell infiltration. Measurable lesions are required. The primary end point was the clinical complete remission rate, and the secondary end point was the degree of focus reduction, the recurrence rate within 12 months after drug withdrawal, the degree of inflammation markers decline, and the toxicity and side effects of the drug.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Baricitinib Baricitinib，2mg QD，oral use. |
Drug: Baricitinib
Baricitinib administered orally
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Clinical Complete Remission Rate(CRR) [Until progression or recurrence, assessed up to approximately 24 months]
CRR defined as the proportion of patients who have a confirmed Complete Remission (CR) , as determined by the investigator at local site per RECIST 1.1.In this study, CR is defined as the complete healing of the lesion and the return of inflammation index to normal level indicated by special physical examination and breast ultrasound.
Secondary Outcome Measures
- The change of lesion diameter [Until progression, assessed up to approximately 24 months]
The change of lesion diameter is measured by special physical examination and breast ultrasound.
- Recurrence rate within 12 months after drug withdrawal [Until progression or recurrence, assessed up to approximately 12 months after drug withdrawal]
Percentage of patients who recur within 12 months after drug withdrawal.
- Degree of inflammation markers change [Until progression, assessed up to approximately 24 months]
Determination the concentration of inflammation markers, such as TNF-α, IL-6, IL-17α and CRP, in serum at different time points after baricitinib administered orally.
- Toxicity and side effects of the drug [Up to follow-up period, approximately 24 months]
Occurrence of adverse events (AEs) after baricitinib administered orally according to NCI CTCAE v5.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must be between 18 years of age and 70 years of age
-
Female patients who have pathologically documented idiopathic granulomatous mastitis that:
-
Non-lactating mastitis
-
Core needle biopsy pathology to indicate mastitis or biopsy pathology of palpable mass indicates chronic interstitial cell infiltration.
-
Special immunohistochemical is negative [Acid fast dyeing, Mayer's dyeing, PAS, fungi (FISH), Tuberculosis (FISH), hexamine silver], excluding the possibility of infection such as fungi, tuberculosis or other corynebacterium.
-
Measurable lesions are required(mainly breast ultrasound can detect lesion with low echo).
-
ECOG Performance Status of 0 or 1,Karnofsky score is greater than 80
Exclusion Criteria:
-
Pregnant women, lactating women or those who have a fertility plan within 3 years; Informed consent does not meet the requirements (if it is not in person, and the authorization consent is missing).
-
Core needle biopsy pathology indicates that inflammation caused by tuberculosis and other pathogenic bacteria infection or any of the above immunohistochemical staining items are positive; Lung (HR) CT showed that tuberculosis or tumor could not be excluded; Misdiagnosis; No test record; There is no record of return visit.
-
Due to the use of other potential therapeutic drugs, such as glucocorticoids or anti-tuberculosis drugs, the effectiveness evaluation of baricitinib cannot be carried out; Those who have been diagnosed as malignant tumors, have been treated or are being treated; Those who have serious complications, such as cardiac or pulmonary insufficiency, severe cerebral infarction, and cannot tolerate the treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang | China |
Sponsors and Collaborators
- First Affiliated Hospital of Zhejiang University
Investigators
- Principal Investigator: Haiyan Wei, Doctor, Zhejiang University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZYYY-IGM-001